Alexion Pharmaceuticals, Inc. | LinkedIn

Typically diagnosed in early childhood, #Neurofibromatosis type 1 (NF1) is a rare, progressive, genetic condition that involves the development of nonmalignant tumours that may affect the brain, spinal cord and nerves. | Alexion Pharmaceuticals

Despite small patient populations, collectively hundreds of people globally are living with a rare disease. It takes around five years to receive a diagnosis, often involving over seven specialists and several misdiagnoses. #RareDiseaseDay #RareDisease | Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. Announces New Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress